These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 7383068)

  • 21. Pharmaceutical research--and the FDA.
    Am Fam Physician; 1978 Jul; 18(1):67-8. PubMed ID: 665475
    [No Abstract]   [Full Text] [Related]  

  • 22. FDA's regulation of prescription drug labeling: a role for implied preemption.
    Kendrick LC
    Food Drug Law J; 2007; 62(1):227-47. PubMed ID: 17444031
    [No Abstract]   [Full Text] [Related]  

  • 23. FDA attempting to overcome major roadblocks in monitoring drug safety.
    Zielinski SL
    J Natl Cancer Inst; 2005 Jun; 97(12):872-3. PubMed ID: 15956645
    [No Abstract]   [Full Text] [Related]  

  • 24. Clinical investigation of new drugs.
    N Engl J Med; 1967 Nov; 277(21):1148-9. PubMed ID: 4861565
    [No Abstract]   [Full Text] [Related]  

  • 25. The evolution of new drug legislation.
    Kelsey FO
    BMQ; 1966 Sep; 17(3):72-81. PubMed ID: 5978212
    [No Abstract]   [Full Text] [Related]  

  • 26. Drugs of limited commercial value.
    Finkel MJ
    N Engl J Med; 1980 Mar; 302(11):643-4. PubMed ID: 7351925
    [No Abstract]   [Full Text] [Related]  

  • 27. Validation--how much can the world afford? Are we getting value for money?
    Anisfeld MH
    J Pharm Sci Technol; 1994; 48(1):45-8. PubMed ID: 8004419
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The final sampling regulations of the Prescription Drug Marketing Act are alive and well: is your sampling program compliant?
    Romanski JA
    Food Drug Law J; 2003; 58(4):649-60. PubMed ID: 15027455
    [No Abstract]   [Full Text] [Related]  

  • 29. The right to a trial: Should dying patients have access to experimental drugs?
    Groopman J
    New Yorker; 2006 Dec; ():40-7. PubMed ID: 17176539
    [No Abstract]   [Full Text] [Related]  

  • 30. Safety considerations in development of new animal drugs.
    Fogleman RW
    J Am Vet Med Assoc; 1972 Dec; 161(11):1381-4. PubMed ID: 4638516
    [No Abstract]   [Full Text] [Related]  

  • 31. [Research in pharmaceutical industry, the driving energy of development].
    Karsenti R
    Cah Sociol Demogr Med; 1978; 18(2):59-68. PubMed ID: 679061
    [No Abstract]   [Full Text] [Related]  

  • 32. The case for preemption of prescription drug failure-to-warn claims.
    Kim CH
    Food Drug Law J; 2007; 62(2):399-422. PubMed ID: 17632969
    [No Abstract]   [Full Text] [Related]  

  • 33. Presumption of innocence: FDA's authority to regulate the specifics of prescription drug labeling and the preemption debate.
    Dorfman HL; Quinn VM; Brophy EA
    Food Drug Law J; 2006; 61(4):585-622. PubMed ID: 17180765
    [No Abstract]   [Full Text] [Related]  

  • 34. The federal preemption debate in pharmaceutical labeling product liability actions.
    Gross JM; Curry JA
    Tort Trial Insur Pract Law J; 2007; 43(1):35-70. PubMed ID: 18354866
    [No Abstract]   [Full Text] [Related]  

  • 35. Unlabeled drug samples and the learned intermediary: the case for drug company liability without preemption.
    Poser S
    Food Drug Law J; 2007; 62(4):653-94. PubMed ID: 18557225
    [No Abstract]   [Full Text] [Related]  

  • 36. Off label drug promotion.
    Body Posit; 1998 Oct; 11(10):11. PubMed ID: 11365909
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Regulatory requirements with regard to the use of investigational new drugs.
    Hodges RM
    Antimicrob Agents Chemother (Bethesda); 1967; 7():16-8. PubMed ID: 5631922
    [No Abstract]   [Full Text] [Related]  

  • 38. Regulating the fate of pharmaceutical drugs: a new prescription for the environment.
    Nidel CT
    Food Drug Law J; 2003; 58(1):81-101. PubMed ID: 12739585
    [No Abstract]   [Full Text] [Related]  

  • 39. Using drugs in food animals.
    Larkin T
    FDA Consum; 1977 Apr; 11(3):6-9. PubMed ID: 10316530
    [No Abstract]   [Full Text] [Related]  

  • 40. Free rein for drug ads? A slowdown in FDA review has left consumers more vulnerable to misleading messages.
    Consum Rep; 2003 Feb; 68(2):33-7. PubMed ID: 12516586
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.